Venture capital and the European biotechnology industry

2009 ◽  
Vol 15 (3) ◽  
pp. 283-284
Author(s):  
Leonard Lerer
Keyword(s):  
Venture Capital ◽  
Biotechnology Industry

Book Review: Venture capital and the European biotechnology industry

1969 ◽  
Vol 15 (3) ◽  
Author(s):  
Leonard Lerer
Keyword(s):  
Venture Capital ◽  
Biotechnology Industry

Venture capital and the European biotechnology industryWilliam BainsPalgrave Macmillan, Basingstoke, 2008, hardback, 232pp.,ISBN: 978-0230217195

Spatial collocation and venture capital in the US biotechnology industry

2011 ◽  
Vol 40 (9) ◽  
pp. 1188-1199 ◽  
Author(s):  
Christos Kolympiris ◽  
Nicholas Kalaitzandonakes ◽  
Douglas Miller
Keyword(s):  
Venture Capital ◽  
Biotechnology Industry ◽  
The Us

scholarly journals 2003: What lessons for European biotechnology?

10.5912/jcb87 ◽  
2004 ◽  
Vol 10 (4) ◽  
Author(s):  
M S Fazeli
Keyword(s):  
Venture Capital ◽  
Biotechnology Industry ◽  
Equity Capital ◽  
Public Markets ◽  
Level Of Activity ◽  
Risk Appetite ◽  
The Us ◽  
The Usa ◽  
Liberal Attitude ◽  
Biotechnology Sector

The biotech sector had a sizzling year last year, raising US$19bn in cash globally. This paper looks at the performance of the biotechnology sector on both sides of the Atlantic in terms of financing activity. Financing activity in the European biotechnology industry is still a long way off from the USA, with public fundraising only reaching the level that the USA had in 1997 and venture capital financings getting close to the US levels of 1994–95. This suggests that at least another five to eight years is needed before there is even a chance to get near where the USA is today. However, the sheer size of the US equity capital market and its liberal attitude to fundraisings and higher-risk appetite is likely to mean that European biotechs will never catch up with the USA, even if our science (across the whole of Europe) is as good. This does not mean that Europe cannot have a thriving biotechnology industry. Indeed, the current level of activity in the venture capital and public markets suggests that Europe is only just getting serious on biotechnology.

scholarly journals The Potential of Biotechnology Investments in Selected Eastern European Countries: Lost Chances

2016 ◽  
Vol 7 (1) ◽  
pp. 16-34
Author(s):  
Patrik Vida
Keyword(s):  
Venture Capital ◽  
Capital Market ◽  
Significant Contribution ◽  
Global Scale ◽  
Biotechnology Industry ◽  
Eastern European ◽  
Business Sector ◽  
Scientific Publications ◽  
Investment Environment ◽  
Eastern European Countries

AbstractBackground:Biotechnology is rapidly developing on a global scale. However, some evidence indicates that Eastern European (EE) countries are not fulfilling their potential in this field.Objectives:This paper aims to examine whether selected EE countries are able to develop a strong biotechnology industry. Potential investment approaches and the existing but not used or neglected infrastructures in EE countries were also examined.Methods/approach:In order to determine biotechnological activities in EE countries, indicators such as intellectual property protection, venture capital availability, published scientific publications as well as other indicators were analyzed. These indicators were compiled and compared between EE countries and regions with a rich and diverse biotechnological business sector.Results:The results suggest an underdeveloped biotechnology business sector in EE countries, with talented but unexploited scientists and unutilized infrastructure. The systematic drawbacks of EE countries lead to a hostile investment environment.Conclusions:The findings make a significant contribution to understanding how the biotechnology industry in EE countries is structured and how investments can be rationally placed. EE countries need to adapt their venture capital market for biotechnology ventures. Several changes in regulations could have a large impact on biotechnology investments.

scholarly journals Multiyear patterns regarding the relative availability of venture capital for the US biotechnology industry

1969 ◽  
Vol 15 (4) ◽  
Author(s):  
J Leslie Glick
Keyword(s):  
Venture Capital ◽  
Early Stage ◽  
Coming Of Age ◽  
Personalised Medicine ◽  
Biotechnology Industry ◽  
Long Run ◽  
Start Up ◽  
The Us ◽  
Biotechnology Companies ◽  
Long Term Trends

Venture capital (VC) funding of US biotechnology companies was analysed relative to total VC investments placed in US companies from 1995 to 2007. During those years, except for a spike because of the dot-com bubble from 1999 to 2001, VC funding of US biotechnology companies grew at a faster rate percentagewise than total VC funding of US companies, with respect to annual dollars invested, number of deals closed and the mean dollar investment. Start-up and early-stage VC funding of US biotechnology companies also grew at a faster rate percentagewise, with respect to all three parameters, than total start-up and early-stage VC funding of US companies. It was further observed that long-term trends in the availability of VC for biotechnology do not appear to be affected by perturbations in the financial markets and short-term fluctuations in the availability of VC. It was concluded that the biotechnology industry should continue to attract VC over the long run particularly because of the emerging impact of personalised medicine and the coming of age of bioenergy.

Sign in / Sign up

Export Citation Format

Share Document